(0.10%) 5 522.25 points
(0.12%) 39 892 points
(0.22%) 19 794 points
(-0.01%) $81.62
(0.60%) $2.83
(-0.31%) $2 337.10
(-0.03%) $29.52
(0.21%) $1 003.90
(0.02%) $0.932
(-0.02%) $10.53
(0.01%) $0.788
(-0.85%) $87.25
11.76% $ 2.28
Live Chart Being Loaded With Signals
Immix Biopharma, Inc., a clinical-stage biopharmaceutical company, engages in developing various tissue-specific therapeutics in oncology and inflammation in the United States and Australia...
Stats | |
---|---|
Dzisiejszy wolumen | 165 134 |
Średni wolumen | 126 414 |
Kapitalizacja rynkowa | 60.22M |
EPS | $-0.220 ( Q1 | 2024-05-09 ) |
Następna data zysków | ( $-0.220 ) 2024-08-09 |
Last Dividend | $0 ( N/A ) |
Next Dividend | $0 ( N/A ) |
P/E |
-2.45 (Sector) 42.63 (Industry) 24.32 |
ATR14 | $0.0240 (1.04%) |
Date | Person | Action | Amount | type |
---|---|---|---|---|
2024-06-11 | Marquet Magda | Buy | 33 000 | Stock Option (Right to Buy) |
2024-06-11 | Chudnovsky Yekaterina | Buy | 33 000 | Stock Option (Right to Buy) |
2024-06-11 | Hsu Jason | Buy | 33 000 | Stock Option (Right to Buy) |
2024-06-11 | Rachman Ilya M | Buy | 340 000 | Stock Option (Right to Buy) |
2024-06-11 | Ng Carey | Buy | 33 000 | Stock Option (Right to Buy) |
INSIDER POWER |
---|
100.00 |
Last 95 transactions |
Buy: 8 946 466 | Sell: 879 400 |
Wolumen Korelacja
Immix Biopharma, Inc. Korelacja
10 Najbardziej pozytywne korelacje | |
---|---|
IRBT | 0.966 |
LGVN | 0.962 |
SIFY | 0.96 |
WALD | 0.957 |
RDHL | 0.957 |
AXDX | 0.956 |
PLL | 0.956 |
INVZ | 0.955 |
CNSP | 0.955 |
EVOK | 0.954 |
10 Najbardziej negatywne korelacje | |
---|---|
ADTH | -0.939 |
FLXS | -0.928 |
FSEA | -0.904 |
INBKZ | -0.902 |
SILK | -0.892 |
OXSQ | -0.892 |
NTNX | -0.891 |
APXI | -0.889 |
AGNCP | -0.888 |
HQY | -0.887 |
Did You Know?
Correlation is a statistical measure that describes the relationship between two variables. It ranges from -1 to 1, where -1 indicates a perfect negative correlation (as one variable increases, the other decreases), 1 indicates a perfect positive correlation (as one variable increases, the other increases), and 0 indicates no correlation (there is no relationship between the variables).
Correlation can be used to analyze the relationship between any two variables, not just stocks. It's commonly used in fields such as finance, economics, psychology, and more.
Immix Biopharma, Inc. Korelacja - Waluta/Towar
Immix Biopharma, Inc. Finanse
Annual | 2023 |
Przychody: | $0 |
Zysk brutto: | $-5 468.00 (0.00 %) |
EPS: | $-0.890 |
FY | 2023 |
Przychody: | $0 |
Zysk brutto: | $-5 468.00 (0.00 %) |
EPS: | $-0.890 |
FY | 2022 |
Przychody: | $-89.52M |
Zysk brutto: | $-89.52M (100.00 %) |
EPS: | $-0.620 |
FY | 2021 |
Przychody: | $0.00 |
Zysk brutto: | $0.00 (0.00 %) |
EPS: | $-2 907.85 |
Financial Reports:
No articles found.
Contract Name | Last Trade Date (EDT) | Strike | Last Price | Bid | Ask | Change | % Change | Volume | Open Interest | Implied Volatility | Strike Date |
---|---|---|---|---|---|---|---|---|---|---|---|
No data available |
Contract Name | Last Trade Date (EDT) | Strike | Last Price | Bid | Ask | Change | % Change | Volume | Open Interest | Implied Volatility | Strike Date |
---|---|---|---|---|---|---|---|---|---|---|---|
No data available |
Immix Biopharma, Inc.
Immix Biopharma, Inc., a clinical-stage biopharmaceutical company, engages in developing various tissue-specific therapeutics in oncology and inflammation in the United States and Australia. The company is developing IMX-110 that is in Phase 1b/2a clinical trials for the treatment of soft tissue sarcoma and solid tumors; IMX-111, a tissue-specific biologic for the treatment of colorectal cancers; and IMX-120, a tissue-specific biologic for the treatment of ulcerative colitis and severe Crohn's disease. It has a clinical collaboration and supply agreement with BeiGene Ltd. for a combination Phase 1b clinical trial in solid tumors of IMX-110 and anti-PD-1 Tislelizumab. The company was incorporated in 2012 and is headquartered in Los Angeles, California.
O Sygnały na żywo
Prezentowane na tej stronie sygnały na żywo pomagają określić, kiedy KUPIĆ lub SPRZEDAĆ BRAK DANYCH. Sygnały mogą mieć opóźnienie wynoszące nawet 1 minutę; jak wszystkie sygnały rynkowe, istnieje ryzyko błędu lub pomyłki.
Sygnały transakcyjne na żywo nie są ostateczne i getagraph.com nie ponosi odpowiedzialności za żadne działania podjęte na podstawie tych sygnałów, jak opisano w Warunkach Użytkowania. Sygnały opierają się na szerokim zakresie wskaźników analizy technicznej